Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 March 2021 | Story University Estates | Photo UFS Photo Archive
The UFS is committed to providing inclusive and accessible living, teaching, and learning spaces that are welcoming to all.

In accordance with its vision to be a university that is recognised across the world for excellence in academic achievement and human reconciliation, the University of the Free State (UFS) is committed to providing a universally accessible environment for all students, staff, and visitors on all three of its campuses. 

A sense of belonging and togetherness

Creating an accessible environment that is conducive and welcoming to everybody on the campuses – which were not designed with accessibility in mind – is not an easy task. When the principles of universal design and access are applied, the environment and spaces can be enjoyed by all users alike, creating a sense of belonging and togetherness. The common perception that accessibility only provides equitable access and opportunities for persons in wheelchairs is refuted by universal access, stating that it is to the advantage and for the use of everybody. Parents with infants in strollers, delivery persons with trolleys or carrying heavy material, library patrons carrying an armful of books, academic staff with wheeled (rolling) laptop bags, and older people all benefit from the availability of a ramp, elevator, or automated door. 

The current accessibility project of the UFS was initiated in 2009, evaluating the accessibility status of the UFS at the time. Priority inaccessible areas and spaces were identified and listed to be converted and improved over a period of five years, revising the list every year. The focus of the project was primarily on areas and spaces where most student activities take place, where specific needs and challenges have been identified, and where specific departments/divisions of the UFS have requested the improvement of access. The project does not only include access to buildings, but also accessible bathrooms, sufficient accessible parking spaces, accessible walkways, and accessibility within the classroom. The emphasis of the project is not only on wheelchair users and persons with mobility impairments, but also on creating an environment that can easily be navigated and used by everybody. 

All new infrastructure incorporates accessibility measures

University Estates updated the accessibility reports mid-2020 and identified project priorities up to 2024. Among other things, the key focus areas were to make all walkways wheelchair-friendly, to create ablution facilities for persons with disabilities, to install lifts in buildings, and to install ramps. All new infrastructure by default incorporates accessibility measures in the planning stage.

On the South Campus, ramps were installed around the campus and pathways were made wheelchair-friendly. Entrances to existing lecture halls and other buildings have also been made more user-friendly for persons with disabilities. Additional to the above-mentioned initiatives, the institution has also embarked on a project that seeks to assist the visually impaired to better navigate the campus.

For our Qwaqwa Campus, immediate critical interventions that are in the planning stage and that should be done within the next year, are the creation of accessible ablution facilities in the Administration Building, library, and the Humanities and Education buildings.

WATCH video below: 


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept